235 related articles for article (PubMed ID: 30636397)
1. Ixekizumab in hidradenitis suppurativa in a psoriatic patient.
Odorici G; Pellacani G; Conti A
G Ital Dermatol Venereol; 2020 Dec; 155(6):788-789. PubMed ID: 30636397
[No Abstract] [Full Text] [Related]
2. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
[No Abstract] [Full Text] [Related]
3. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
Yen CF; Huang YH; Chi CC
Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
[No Abstract] [Full Text] [Related]
5. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
6. Successful use of guselkumab in the treatment of severe hidradenitis suppurativa.
Kearney N; Byrne N; Kirby B; Hughes R
Clin Exp Dermatol; 2020 Jul; 45(5):618-619. PubMed ID: 32068912
[No Abstract] [Full Text] [Related]
7. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.
Saraceno R; Babino G; Chiricozzi A; Zangrilli A; Chimenti S
J Am Acad Dermatol; 2015 Jan; 72(1):e42-4. PubMed ID: 25497954
[No Abstract] [Full Text] [Related]
8. Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab.
Erten S
Rheumatol Int; 2011 Nov; 31(11):1537-8. PubMed ID: 21120492
[No Abstract] [Full Text] [Related]
9. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
Tampouratzi E; Kanni T; Katsantonis J; Douvali T
F1000Res; 2019; 8():2002. PubMed ID: 33456757
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with Secukinumab.
Kontochristopoulos G; Kanni T; Marnelakis I; Agiasofitou E; Liakou A; Rigopoulos D
Skinmed; 2023; 21(1):57-58. PubMed ID: 36987833
[No Abstract] [Full Text] [Related]
11. Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
Ann Intern Med; 2012 Dec; 157(12):I-50. PubMed ID: 23247950
[No Abstract] [Full Text] [Related]
12. Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa.
Vignoli CA; Gargiulo L; Sanna F; Narcisi A; Costanzo A
J Dermatolog Treat; 2023 Dec; 34(1):2256905. PubMed ID: 37705359
[No Abstract] [Full Text] [Related]
13. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis.
Bougea A; Anagnostou E; Stamboulis E; Kararizou E
Rev Neurol (Paris); 2014 Mar; 170(3):228-9. PubMed ID: 24656415
[No Abstract] [Full Text] [Related]
14. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
15. New treatments for PsA meet targeted therapy goals.
Mease PJ
Nat Rev Rheumatol; 2021 Feb; 17(2):77-78. PubMed ID: 33328615
[No Abstract] [Full Text] [Related]
16. Psoriasis treatment in patients with sickle cell disease.
Pulusani S; McMurray SL; Jensen K; Jones AV
Cutis; 2019 Feb; 103(2):93-94. PubMed ID: 30893386
[TBL] [Abstract][Full Text] [Related]
17. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
18. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on 'Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab'.
Martora F; Fabbrocini G; Marasca C; Battista T; Megna M
Clin Exp Dermatol; 2023 Jun; 48(6):701-703. PubMed ID: 36883596
[No Abstract] [Full Text] [Related]
20. Alopecia areata universalis elicited during treatment with adalimumab.
Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
